NFKB1 and atherosclerosis: In atherosclerosis, PDCD4, as a target of miR-16, may inhibit the activation of inflammatory macrophages via the mitogen-activated protein kinase (MAPK) and NF-κB and signaling pathways, suggesting that PDCD4 could be a focus of atherosclerosis therapy [36].